Kallik Founder Recognised as One of Global Pharma Sectors Most Valuable Contributors
Labelling content and artwork management leader Kallik is delighted to announce that its founder and CEO Neil Gleghorn has just been recognised as one of the 100 most influential people on the global pharmaceutical stage.
The honour is confirmed by Neil being named to the landmark PharmaVOICE 100 List published by the sector’s leading independent editorial publication, PharmaVOICE.
Established 9 years ago, The PharmaVOICE 100 is an annual list of individuals determined by their peers as having made the most consistent, outstanding contribution to the life sciences industry, an industry whose UK representatives generate over £50 billion in sales every year according to government statistics.
According to the publishers, winners of PharmaVOICE 100 places illustrate what it means to think bigger, do more, and lead with passion and integrity, with all nominations decided by members of the sector.
“I am extremely honoured to receive this industry recognition,” said Neil.
“It is one of the most important peer awards in the pharmaceutical industry, and is testament to the work of everyone here at Kallik — not just me, but everyone from the most junior team member all the way up to the board, our partners and everyone who’s been part of the journey – and most important of all, our customers.”
A Long-Lasting Dialogue
Neil’s extensive knowledge and understanding of the pharma industry’s specific challenges was key to his winning a PharmaVOICE 100 place.
That is a knowledge base that he has used to develop forward-thinking solutions that help achieve efficiency and compliance as well as form the basis for on-going dialogues with customers about the long-term challenges they face.
“What a third party like a Kallik can do is see the gaps that siloed teams in procurement, regulatory or marketing in a pharmaceutical company just can’t,” he said. “We use that perspective to develop the kind of systems that the pharmaceutical companies of today are increasingly recognising as vital in maximising their opportunity in the market.”
Related News
-
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Pharma Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain. -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement. -
News BIOSECURE Act continues to loom over Chinese pharma manufacturers
With the US BIOSECURE Act on its way to passing into legislation, Chinese companies are facing declining revenues within the first half of 2024 as US pharmaceutical and healthcare companies pull their businesses from the country. -
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance